IC
QNCX icon

Ikarian Capital’s Quince Therapeutics QNCX Stock Holding History

Ikarian Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-850
Closed -$4.72M – 328
2020
Q4 		$4.72M Buy
850
+835
+5,567% +$7.4M 0.21% 97
2020
Q3 		$150K Buy
+15
New +$136K 0.01% 163

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ikarian Capital's QNCX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 72,251 shares worth $1.31M. The stake represents 0.14% of the portfolio and ranks #99 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in QNCX as recently as Q3 2021.

Ikarian Capital first reported a position in QNCX in Q1 2020 and has held it in 6 quarters since. The position peaked at $2M in Q3 2020. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Ikarian Capital held 72,251 shares of Quince Therapeutics worth $1.31M as of Q2 2026.
  • Quince Therapeutics was a new Ikarian Capital position in Q2 2026.
  • Quince Therapeutics made up 0.14% of Ikarian Capital's portfolio in Q2 2026, its #99 holding.
  • Ikarian Capital first reported a position in Quince Therapeutics in Q1 2020 and has held it in 6 quarters since.
  • Ikarian Capital's Quince Therapeutics position peaked at $2M in Q3 2020.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.